2011
Chapter 41 Parathyroid Hormone, Parathyroid Hormone-Related Protein, and Calcitonin
Holt E, Wysolmerski J. Chapter 41 Parathyroid Hormone, Parathyroid Hormone-Related Protein, and Calcitonin. 2011, 725-745. DOI: 10.1016/b978-0-12-381978-9.10041-1.Peer-Reviewed Original ResearchParathyroid hormoneParathyroid hormone-related proteinMedullary thyroid cancerSerum tumor markersSigns of recurrenceEffect of calcitoninTreatment of osteoporosisMedullary thyroid carcinomaHormone-related proteinTreatment of boneIntermittent administrationCalcium disordersThyroid cancerSmooth muscleThyroid carcinomaAnabolic responseTumor markersUseful agentBaseline levelsPTH analogsCardiovascular systemCalcitoninGrowth factorMammary glandLongitudinal monitoring
2002
Treatment of Osteoporosis and Osteopenia in Long‐term Renal Transplant Patients with Alendronate
Cruz DN, Brickel HM, Wysolmerski JJ, Gundberg CG, Simpson CA, Kliger AS, Lorber MI, Basadonna GP, Friedman AL, Insogna KL, Bia MJ. Treatment of Osteoporosis and Osteopenia in Long‐term Renal Transplant Patients with Alendronate. American Journal Of Transplantation 2002, 2: 62-67. PMID: 12095058, DOI: 10.1034/j.1600-6143.2002.020111.x.Peer-Reviewed Original ResearchConceptsBone mineral densityHigh bone turnoverRenal transplant patientsBone lossBone turnoverTransplant patientsTotal femurLumbar spineLong-term renal transplant patientsLong-term renal transplant recipientsBiochemical markersBiochemical parametersGood renal functionGroup A patientsRenal transplant recipientsBone turnover markersRegional bone mineral densityTreatment of osteoporosisSerum alkaline phosphataseFirst yearBisphosphonate therapyTransplant recipientsAlendronate therapyRenal functionA patients